Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human Interaction Clear all
Completed No phase listed Observational Accepts healthy volunteers

Do Bonding Disruptions Occur More Often in Children With Asthma Than in Non-asthmatic Populations?

NCT02158338
View directory record Official record
Conditions
Asthma in Children, Anxiety
Interventions
Asthma, Non-asthma
Other
Lead sponsor
Ran Anbar
Other
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 2, 2026, 5:43 PM EDT
Terminated Phase 2 Interventional Results available

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

NCT05200143
View directory record Official record
Conditions
Refractory Cutaneous Melanoma
Interventions
Ipilimumab, Nivolumab, Cabozantinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

NCT03084471
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interaction Effects of Temperature and Ozone

NCT01981135
View directory record Official record
Conditions
Exposure to Environmental Pollution, Non-occupational
Interventions
Clean Air, Ozone
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants

NCT07629999
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986533, Famotidine, Placebo, Dabigatran Etexilate, Rosuvastatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

NCT04963283
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma, Rectum Cancer, Rectal Cancer, Rectal Adenocarcinoma, Colorectal Cancer
Interventions
Cabozantinib, Nivolumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Coaching Alternative Parenting Strategies (CAPS) Study

NCT02684903
View directory record Official record
Conditions
Child Abuse, Self-control, Parenting
Interventions
Parent Child Interaction Therapy
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
3 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Doxycycline in Humans

NCT00964834
View directory record Official record
Conditions
Anthrax
Interventions
Doxycycline and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Digital Mental Health Service for Non-Treatment Seeking Young Adults

NCT04948268
View directory record Official record
Conditions
Depression, Anxiety, Suicidal Ideation
Interventions
Adaptive messaging intervention, Non-personalized messaging intervention, Coaching, Psychoeducational links
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 25 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Plant Pigments for Human Health: Impact of Lycopene and Anthocyanins on Bioefficacy of Provitamin A Carotenoids From Carrots

NCT05319548
View directory record Official record
Conditions
Healthy
Interventions
Purple-Red Carrot Juice, Red Carrot Juice, Purple Carrot Juice
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention

NCT04885166
View directory record Official record
Conditions
Prescription Drug Abuse (Not Dependent), Intentional Misuse
Interventions
Web-based placebo presentation, Web-based simulation active intervention
Other · Behavioral
Lead sponsor
Trinity College
Other
Eligibility
17 Years to 25 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hartford, Connecticut • San Marcos, Texas • Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Active, not recruiting Not applicable Interventional

I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms in Hispanic Individuals

NCT06099197
View directory record Official record
Conditions
Caregiver Burden, Alzheimer Disease
Interventions
Brain CareNotes, Dementia Guide Expert
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Effects of Human-Animal Interaction on Anxiety in Graduate Students

NCT07036354
View directory record Official record
Conditions
Human-animal Interaction, Anxiety
Interventions
Human-Animal Interaction, General Health Education
Other
Lead sponsor
Wichita State University
Other
Eligibility
20 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Not applicable Interventional

I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms

NCT05733520
View directory record Official record
Conditions
Caregiver Burden, Alzheimer Disease
Interventions
Brain CareNotes, Dementia Guide Expert
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Enhancing BodyWorks: A Canine Health Literacy Module

NCT04516252
View directory record Official record
Conditions
Overweight and Obesity, Overweight Adolescents
Interventions
BodyWorks Intervention, Canine Curriculum, Ecological Momentary Assessment, Physical Activity Trackers
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
9 Years to 17 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

NCT01318265
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Sep 2, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

NCT04150900
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Bavituximab, Pembrolizumab
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy

NCT06859710
View directory record Official record
Conditions
Abuse, Drug, Pain
Interventions
Placebo, THC, CBD 20 mg, CBD 40 mg, CBD 80 mg
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 2, 2026, 5:43 PM EDT
Recruiting Not applicable Interventional

Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's

NCT05748613
View directory record Official record
Conditions
Anxiety, Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Computerized Anxiety Sensitivity Treatment, Health Education Control
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
60 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Tallahassee, Florida • Athens, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 5:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

NCT03543189
View directory record Official record
Conditions
Prostate Cancer, Prostate Disease
Interventions
Nivolumab, Brachytherapy, External Beam Radiation Therapy, Androgen Deprivation Therapy
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 2, 2026, 5:43 PM EDT